Biocon Biologics Inks Pact with JJ and Janssen Arms to Market ‘Bmab’ in Europe and Japan, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Biocon Biologics Inks Pact with JJ and Janssen Arms to Market ‘Bmab’ in Europe and Japan, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Bengaluru: Biocon Biologics Ltd (BBL), a biosimilars company and a subsidiary of Biocon Ltd, announced that it has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize its psoriasis *****, Bmab 1200, in Europe, particularly the ******* Kingdom (***), Canada, and Japan.

Under the terms of the settlement agreement, the biosimilar company has resolved patent disputes with Janssen to secure market entry dates in the aforementioned markets, while the regulatory filings for the ***** are currently under review, the company stated in a release.

“This settlement agreement is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab) to global markets. Bmab 1200 will significantly strengthen our immunology franchise, enabling us to offer an affordable and effective treatment option for patients impacted by autoimmune *********,” Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd, said.

Bmab 1200 is a proposed biosimilar to Stelara (Ustekinumab), a monoclonal antibody medication that prevents abnormal regulation of interleukin IL-12/23 associated with immune *********. It has been approved for the treatment of psoriasis, Crohn’s ********, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, according to the release.

According to Johnson & Johnson’s reported sales figures for 2023, Stelara registered global sales of $10.85 billion.

Notably, Biocon had earlier announced a settlement agreement in the ******* States for the same *****, with a planned launch no later than February 22, 2025, pending approval by the U.S. FDA. The regulatory authority has accepted the company’s Biologics License Application (BLA) for review under the 351(k) pathway.

• Published On Aug 29, 2024 at 11:15 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#Biocon #Biologics #Inks #Pact #Janssen #Arms #Market #Bmab #Europe #Japan #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up